As mentioned previously, molecular characterization of GBM cell lines derived from NULU and ZAR patients revealed the unmethylated profile of the MGMT gene promoter and, consequently, a drug-resistance phenotype to standard TMZ chemotherapy. Here, MGMT is linked to glioblastoma.